Factors independently prognostic of freedom from progression and overall survival
| Variable . | Freedom from progression survival . | Overall survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| β . | SE . | RR . | P . | β . | SE . | RR . | P . | |
| NHL patients (n = 204) | ||||||||
| IPI | 0.305 | 0.067 | 1.35 | <.0001 | 0.355 | 0.051 | 1.42 | <.0001 |
| TNF-308A | 0.491 | 0.072 | 1.63 | <.0001 | 0.411 | 0.055 | 1.51 | <.0001 |
| Null HLA DRB1*02 | 0.171 | 0.070 | 1.18 | <.02 | 0.226 | 0.053 | 1.25 | <.0001 |
| DLBCL patients (n = 104) | ||||||||
| IPI | 0.427 | 0.083 | 1.53 | <.0001 | 0.459 | 0.070 | 1.58 | <.0001 |
| TNF-308A | 0.422 | 0.084 | 1.52 | <.0001 | 0.359 | 0.071 | 1.43 | <.0001 |
| Null HLA DRB1*02 | 0.133 | 0.083 | 1.14 | =.10 | 0.177 | 0.070 | 1.19 | <.01 |
| Variable . | Freedom from progression survival . | Overall survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| β . | SE . | RR . | P . | β . | SE . | RR . | P . | |
| NHL patients (n = 204) | ||||||||
| IPI | 0.305 | 0.067 | 1.35 | <.0001 | 0.355 | 0.051 | 1.42 | <.0001 |
| TNF-308A | 0.491 | 0.072 | 1.63 | <.0001 | 0.411 | 0.055 | 1.51 | <.0001 |
| Null HLA DRB1*02 | 0.171 | 0.070 | 1.18 | <.02 | 0.226 | 0.053 | 1.25 | <.0001 |
| DLBCL patients (n = 104) | ||||||||
| IPI | 0.427 | 0.083 | 1.53 | <.0001 | 0.459 | 0.070 | 1.58 | <.0001 |
| TNF-308A | 0.422 | 0.084 | 1.52 | <.0001 | 0.359 | 0.071 | 1.43 | <.0001 |
| Null HLA DRB1*02 | 0.133 | 0.083 | 1.14 | =.10 | 0.177 | 0.070 | 1.19 | <.01 |
β indicates regression coefficient; SE, standard error of β; RR, relative risk (eβ); NHL, non-Hodgkin lymphoma; TNF, tumor necrosis factor, DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index.